illumina inc shares sank more than 22 after hours thursday after the genesequencing company swung to a loss in the second quarter fell short of revenue expectations and revised its fullyear outlook downward francis desouza chief executive of illumina said in a statement that the quarterly results failed to meet the company’s own expectations because “challenges in a complex macroeconomic environment more than offset the growth we continue to see in sequencing runs on our platforms” illumina ilmn reported a loss of 535 million or 340 a share compared with net income of 187 million or 126 a share in the yearago period adjusted for 609 million in legal contingencies plus selling general and administrative expenses and other costs earnings were 57 cents a share revenue rose to 116 billion from 113 billion in the yearago quarter analysts surveyed by factset had forecast earnings of 64 cents a share on revenue of 122 billion the company said in a news release that it expects fullyear revenue for 2022 to grow 4 to 5 from fiscalyear 2021 citing “ongoing negative impact of foreign exchange rates customer lab expansion delays and macroeconomicdriven conservatism around immediate capital and inventory commitments including in greater china” last quarter the company said it expected 14 to 16 revenue growth for fiscalyear 2022 shares of illumina have decreased 40 year to date while the sp 500 index spx has fallen almost 12 during the same period the company’s stock dropped sharply in june after it announced that its chief financial officer was leaving for quest diagnostics inc dgx 